Abbvie’s RINVOQ® (upadacitinib) Approved by U.S. FDA as an Oral Treatment for Adults with Active Ankylosing Spondylitis May 4, 2022 | BioForward Member News Read the full Abbvie press release here
Oct 08 2024 The world is a small place! Opportunities for experiential learning and study abroad to advance OneHealth
Oct 09 2024 A multidisciplinary approach to global pandemic response: Internship and research opportunities with Stellenbosch University